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A B S T R A C T
Background: Refractory status epilepticus (RSE) is a common Neurological Emergency with increased
mortality and morbidity in developing countries where facilities of intubation, adequate ventilation,
Intensive Care Units (ICUs) and general anaesthesia are not ubiquitously available. Treatment protocols
use antiepileptic drugs (AEDs) and need ICU facilities after failure of standard AEDs. Our aim was to see
the response to two additional drugs in the armamentarium against refractory status, that is, valproate
and levetiracetam.
Methods: Patients with generalized RSE admitted in neurology and neurosurgery services at AIIMS
during December 2006 to June 2008were included in the study. The patients were allotted to two groups
based on certain criteria. Demographic details, reason for delay, etiology precipitating status, ongoing
AEDs therapy, duration of status, the time taken for cessation along with clinical, EEG andMRI correlates
were noted. Outcome parameters were analyzed by an independent blinded observer.
Results: 82 patients with RSE were studied out of which 41 patients were given IV valproate (Group A)
and 41 patients were given IV levetiracetam (Group B). Cessation of status failed in 13 patients in
valproate group and 11 patients in levetiracetam group. Majority of the patients did not require ICU
settings despite being classiﬁed as refractory.
Conclusion: RSE can be controlled with intravenous loading and maintenance of valproate or
levetiracetam which do not cause respiratory depression, hypotension, need of intubation and ICU
care. These must always be considered in a developing country scenario where ICU facilities are not
always available or while transporting to centres where these facilities are available.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The earliest known description of status epilepticus was in the
25th and 26th tablets of the Sakikku cuneiform of the Neo-
Babylonian era, written during 718–612 BC.1 The operational
deﬁnition of status epilepticus is an empirical compromise
dictated by therapeutic needs, because treatment should not be
delayed until patients are in established status epilepticus, when
neuronal injury and time-dependent development of pharma-* Corresponding author at: Department of Neurology, Room No. 705, Neuros-
ciences Centre, All India Institute ofMedical Sciences, NewDelhi 110029, India. Tel.:
+91 26594494/26588248; fax: +91 26588248/26588166.
E-mail addresses: manjari.tripathi@gmail.com (M. Tripathi),
deeptivibha@yahoo.com (D. Vibha), navitachoudhary@gmail.com (N. Choudhary),
drkameshwarprasad@yahoo.co.in (K. Prasad), vasanthapadma123@rediffmail.com
(M.V. Padma Srivastava), rohitbhatia71@yahoo.co.in (R. Bhatia),
saratpchandra@gmail.com (S.P. Chandra).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.11.007coresistance have occurred.2 In its most severe form, refractory SE
(RSE), continuous or repetitive seizures do not respond to
benzodiazepines such as lorazepam and phenytoin-therapy.3,4
Refractory status epilepticus (RSE) has been deﬁned as seizures
lasting >60 min, despite treatment with benzodiazepines (BZDs)
and adequate antiepileptic medications (AEDs), or persistence of
discrete seizures without return to baseline even with appropriate
therapy. Randomized controlled trials comparing treatment
strategies for RSE have not been performed to date, to our
knowledge. RSE occurs in approximately 30% of patients with SE
and is associated with increased hospital length of stay and
functional disability andmorbidity.5 There should be no hesitation
to intubate and severe arterial hypotension should be avoided
because as it will curtail the cerebral blood ﬂow.2 However, in
developing countries where facilities of intubation, adequate
ventilation, Intensive Care Units and general anaesthesia are not
always available,6 need for an alternative AEDswhich can abort the
need for ventilation and buy time for transportation to a centrevier Ltd. All rights reserved.
Table 3
Outcomes in Groups A and B.
Outcome Group A (n=41) Group B (n=41)
Cessation from status 26 (68.3%) 28 (73.2%)
Required intubation 13 (31.7%) 11 (26.8%)
Days of ICU (mean) 9 7.6
Death 2 (4.8%) 2 (4.8%)
Table 1
Baseline characteristics of patients.
Variable Group A (n=41) Group B (n=41) p-Value
Age (years) b 26.6210.1 21.089.7 0.112
Male gender 19 (46.3) 23 (56.1) 0.402
Duration of epilepsy (years)a 5 (0–18) 3 (0–11) 0.017*
Duration of SE (h)a 4 (1–48) 5 (2–84) 0.315
Distance (h)a 2 (1–12) 2 (1–20) 0.616
a Median (minimummaximum).
b Mean standard deviation.
* p-Value<0.05.
Table 2
Etiology of status.
Variable Group A (n=41) Group B (n=41) p-Value
Noncompliance 10 12 0.248
Metabolic 2 3 0.532
Acute systemic infection 5 3 0.142
CNS etiology 18 16 0.295
Unascertainable 6 7 0.512
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studies with valproate and levetiracetam earlier with favourable
results.11–15,19–24
2. Patients and methods
All adults (age > 14 years) with refractory status epilepticus
(RSE), which was deﬁned as seizures lasting for more than 60 min
(5) and had to have received intravenous lorazepam and phenytoin
already. All patients included were admitted in neurology and
neurosurgery services (unit 1) at AIIMS over a period of December
2006 to June 2008. The recruitment was done after approval from
the Institute Ethics Committee and informed consent was taken.
The patients were allotted in two groups. Patients who had no
contraindication to valproate and could not afford levetiracetam
for continuation therapy were assigned treatment in Group A.
Patients who had contraindication to IV valproate or could afford
continuation therapy of levetiracetam were assigned Group B.
Patients who had contraindications to valproate and could not
afford levetiracetam for continuation therapies were excluded
from the study. Patients with nonconvulsive and subtle SE,
pregnancy, those requiring immediate neurosurgical intervention,
patients who had received any or both of the treatments prior to
arrival at our Emergency room, patients who were brought
intubated or had to be intubated in the Emergency services, were
excluded. Demographic and clinical details like gender, age,
duration of epilepsy (in years), duration of status epilepticus (in
hours), duration of delay in reaching hospital, reasons for delay in
reaching the hospital, AED(s) the patient was on, and the etiology
of status were noted.
Further, during the hospital stay, the outcome, duration taken
for the cessation of status epilepticus, further need for intubation,
ICU care and days spent in ICU were also noted.
The valproate group was loaded with 30 mg/kg of intravenous
valproate at the rate of 5 mg/kg/min was done. The levetiracetam
group received intravenous dose of 30 mg/kg at the rate of 5 mg/
kg/min. Both were generic intravenous preparations. Primary
outcome was deﬁned as clinical seizure cessation after infusion
and secondary outcome as seizure freedom at 24 h. EEG was
performed for aminimumof 1 h, after clinical control of convulsion
if the consciousness did not improve however in 22 patients
continous EEG could be done for 72 h after clinical cessation of
seizures (Nicolet-Viasys).
The evaluator was blinded to the treatment arm the patient was
assigned to and the administrationwas done by senior residents on
emergency call on a particular day in the hospital. EEG was read by
the evaluator (MT).
3. Statistical analysis
The data was entered in Microsoft Excel and was analysed by
using SPSS version 15 using LEADTOOLS technology. Student t-test
was used for comparing continuous variables between the two
groups. The qualitative data was analysed by using Pearson chi
square/Fischer’s exact test wherever applicable. Besides this, the
odds ratio and 95% conﬁdence interval were also calculated. Log
transformation was also applied to normalize skewed data.
4. Results
During the study period, 209 patients of RSE were admitted. Of
these, 127patientswere excluded (105patientswere eitherbrought
intubated or had to be intubated in Emergency services and 23
patients had received any or both of the treatment drugs prior to
their arrival in AIIMS). 82 patients with the criteria of refractory
generalized status epilepticus were studied in which 41 patientswere given IV valproate (Group A) and 41 were given IV
levetiracetam (Group B). This was prior to availability of ICU beds
(only 5 ICUbeds at this centre). Their age ranged from14 to35years.
All baseline characteristics were comparable in both groups except
for duration of epilepsy which was higher in Group A (Table 1).
Underlying cause was cryptogenic in 13 patients, neurocysti-
cercosis (NCC) in 9, post-traumatic gliosis in 6, alcohol/metabolic
in 5, Mesial Temporal Sclerosis (MTS) in 4, peripartum Cerebral
Venous Thrombosis (CVT), stroke and post-encephalitis in 3 each,
perinatal insult and cortical dysplasia in 2 each, tuberculoma and
Juvenile Myoclonic Epilepsy (JME) in 1 each. There was no
difference in the etiology of status in either group (Table 2).
Reasons for delay to the hospital were lack of knowledge in 30
patients, ﬁnancial in 9, distance in 8, superstition in 2, and panic in
3. Six patients were not on any AEDs, 13 patients on 1 AED, 15
patients on 2 AEDs, 14 patients on 3 AEDs, and 4 patients on 4
AEDs. 13 patients in Group A and 11 patients in Group Bwent on to
acquire intubation and 2 in each group eventually died. Days of ICU
stay in each group were 9 and 7.6 days in Groups A and B
respectively (p-value = 0.90) (Table 3).
Majority of the patients did not require ICU settings despite
being classiﬁed as refractory. 13 (31.7%) patients in Group A and 11
(26.8%) patients in Group B could not be controlled and required
intubation and administration of propofol or midazolam continu-
ous infusion (p = 0.696). No adverse events like hepatic dysfunc-
tion, hypotension, behaviour abnormalities, respiratory depression
or thrombocytopenia were reported in any group.
Thus, the efﬁcacy of Group A was 68.3% and of Group B was
73.2% and the difference was not signiﬁcant. Themean numbers of
days spent in hospital were 14.8 days in Group A and 14.33 days in
Group B (p = 0.903).
5. Discussion
Intravenous valproate was ﬁrst used intravenously in 19787
andwas administered for SE in 1993 by Giroud et al.8 Studies in the
M. Tripathi et al. / Seizure 19 (2010) 109–111 111last decade found it safe as a rapid intravenous infusion for control
of status epilepticus.9,10 It was only in this decade that a series of
studies realized it to be a better choice in patients who had
contraindications to phenytoin, were in hypotension. In a country
with limited resources it could buy time before the patient can be
placed in ICU due to a severe mismatch between resources and the
population load.11–13 There have been recent trials comparing it to
intravenous phenytoin and have found it to be equally safe and
have higher efﬁcacy.14,15 Intravenous valproate has been incorpo-
rated in treatment protocols of treatment of status epilepticus in
the recently published studies.2,16,17
Intravenous levetiracetam has been added later in the
armamentarium of AEDs which can be used in treatment of status
epilepticus.18 Favourable results have so far been only supple-
mented by case reports and retrospective case series.19,20–24
Our study is the ﬁrst, to the best of our knowledge to have
prospectively studied the administration of these AEDs before the
tertiary drugs for the control of RSE and shown that they can delay
and defer the need of intubation and the resultant systemic
complications and are without any major side effects in an adult
population. This has been done in a very naturalistic setting as
treatment trials in status epilepticus are difﬁcult to perform. Hence,
theprearrangedcriteriawereusedforchoosingonedrugortheother.
The limitations of our study are that the medication was not
masked and the administrators knewwhat the patientwas getting.
The sample size is not too large but considering the fact that
virtually no home based prehospital treatment by emergency
paramedical staff exists in our country any study looking into the
treatment prospects of status in a developing country is a drop in
the ocean. However our results need conﬁrmation in a larger study.
6. Conclusion
This study adds the choice of two more good antiepileptic
agents in the management of status epilepticus. Both can be used
conﬁdently in the same andmust be consideredwhile awaiting ICU
facilities for status.
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